PolyPid Ltd. (PYPD)
| Market Cap | 135.80M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 38.98M |
| Shares Out | 18.76M |
| EPS (ttm) | -3.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $7.24 |
| Previous Close | $7.14 |
| Change ($) | 0.10 |
| Change (%) | 1.40% |
| Day's Open | 7.09 |
| Day's Range | 7.09 - 7.40 |
| Day's Volume | 8,155 |
| 52-Week Range | 6.95 - 16.50 |
Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT
PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-...
PolyPid Ltd (NASDAQ: PYPD) has received written responses from the FDA to a Type B meeting request that the company submitted regarding its development plan for its lead candidate, D-PLEX100. The FDA in...
• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery
PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, e...
Top-line Data Anticipated by Year End 2021
PETAH TIKVA, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-...
PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...
Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemothe...
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged...
PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q3 2020 Results - Earnings Call Transcript
• Over 50% of p lanned 60 centers for ongoing Phase 3 SHIELD I t rial of D-PLEX 100 in a bdominal s urgery have r eceived IRB approval
PETAH TIKVA, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...
PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-...
PolyPid Ltd. (PYPD) CEO Amir Weisberg on Q2 2020 Results - Earnings Call Transcript
Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDA
PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonge...
PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonge...
PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonge...
Polypid starts phase 3 trial in prevention of post-abdominal surgery incisional infection.
PolyPid disclosed Monday that it set terms for its initial public offering, in which the Israel-based biopharmaceutical company expects to raise up to $53.1 million. The company is offering 3.125 milli...
About PYPD
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Industry Biotechnology | IPO Date Jun 26, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol PYPD |
Analyst Forecasts
According to 3 analysts, the average rating for PolyPid stock is "Buy." The 12-month stock price forecast is 25.80, which is an increase of 256.35% from the latest price.